Neurocrine Biosciences, Inc. (LON:0K6R)

Market Cap	9.65B
Revenue (ttm)	1.83B
Net Income (ttm)	254.22M
Shares Out	n/a
EPS (ttm)	2.48
PE Ratio	37.97
Forward PE	14.58
Dividend	n/a
Ex-Dividend Date	n/a

Volume	121
Average Volume	168
Open	126.54
Previous Close	130.95
Day's Range	125.13 - 127.84
52-Week Range	84.36 - 157.80
Beta	n/a
RSI	41.69
Earnings Date	Jul 31, 2025

About HashiCorp

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1992
• Employees: 1,800
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0K6R

Financial Performance

In 2024, Neurocrine Biosciences's revenue was $2.36 billion, an increase of 24.81% compared to the previous year's $1.89 billion. Earnings were $341.30 million, an increase of 36.68%.